Lv71
3640 积分 2020-09-07 加入
Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer
4小时前
待确认
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
4小时前
待确认
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
4小时前
待确认
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
5小时前
待确认
Thermal immuno-nanomedicine in cancer
9小时前
待确认
Targeting the tumour cell surface in advanced prostate cancer
14天前
已完结
Synergistic targeting strategies for prostate cancer
14天前
已完结
Assessment of a Polygenic Risk Score in Screening for Prostate Cancer
1个月前
已完结
Microultrasonography-guided prostate cancer biopsy
1个月前
已完结
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
1个月前
已完结
皖公网安备34019202002308
